A phase I trial of carlumab, a CCL2 monoclonal antibody, in solid tumor patients, included eight ovarian cancer patients, and 1/8 of patients had a stable disease at 10.5 months [111]. This evidence concerns the gene CCL2 and ovarian carcinoma.